mAbxience Revenue and Competitors
Estimated Revenue & Valuation
- mAbxience's estimated annual revenue is currently $169.3M per year.
- mAbxience's estimated revenue per employee is $170,970
Employee Data
- mAbxience has 990 Employees.
- mAbxience grew their employee count by 11% last year.
mAbxience's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Development Officer - Member the Executive Committee, mAbxience | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | Head Analytical development | Reveal Email/Phone |
5 | Head Regulatory Operations | Reveal Email/Phone |
6 | Controller technician | Reveal Email/Phone |
7 | Global Quality Director | Reveal Email/Phone |
8 | Global Commercial Director | Reveal Email/Phone |
9 | Associate Director Regulatory Affairs CMC | Reveal Email/Phone |
10 | Director médico | Reveal Email/Phone |
mAbxience Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $10.4M | 48 | -13% | N/A | N/A |
#2 | $42.9M | 220 | -3% | N/A | N/A |
#3 | $53.3M | 212 | -25% | N/A | N/A |
#4 | $169.3M | 990 | 11% | N/A | N/A |
#5 | $13.6M | 80 | 11% | N/A | N/A |
#6 | $25.9M | 141 | 3% | N/A | N/A |
#7 | $26.5M | 199 | 42% | N/A | N/A |
#8 | $8.8M | 51 | 9% | N/A | N/A |
#9 | $11.8M | 76 | 4% | N/A | N/A |
#10 | N/A | 60 | 20% | N/A | N/A |
What Is mAbxience?
mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.
keywords:N/AN/A
Total Funding
990
Number of Employees
$169.3M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 992 | 13% | N/A |
#2 | N/A | 1000 | 19% | N/A |
#3 | N/A | 1003 | 3% | N/A |
#4 | $349M | 1003 | 3% | N/A |
#5 | N/A | 1008 | 178% | N/A |